SI-BONE Earnings Call Transcripts
Fiscal Year 2026
-
The company has evolved into a multi-product platform targeting a $3.5B TAM, with strong growth in SI joint, trauma, and pelvic fixation markets. Physician base and sales force expansion, new product launches, and partnerships like Smith+Nephew are expected to drive accelerated growth and improved reimbursement through 2028.
-
The meeting covered director elections, auditor ratification, and executive compensation, all of which were approved. No questions were raised, and a quorum was established with nearly 88% of shares represented. Final voting results will be filed on Form 8-K.
-
Momentum is driven by innovation, expanding physician adoption, and strategic partnerships, with new products and reimbursement changes expected to accelerate growth and profitability through 2026 and beyond. Gross margins remain strong near 80%, and operating leverage is set to improve.
-
Q1 2026 saw 11% revenue growth, strong operating leverage, and raised full-year guidance. New product launches, a key partnership, and favorable CMS reimbursement changes are expected to accelerate growth, with a breakthrough device launch and expanded sales force supporting future momentum.
-
The company is expanding its portfolio and market reach through physician-driven innovation, strategic partnerships like Smith+Nephew, and a robust pipeline targeting unmet needs in spine and trauma. Strong growth, margin focus, and regular new product launches are expected to drive performance through 2028.
Fiscal Year 2025
-
Record 2025 revenue and first full year of positive adjusted EBITDA highlight strong execution, with robust physician adoption, new product launches, and favorable reimbursement driving growth. 2026 guidance anticipates 14–16% revenue growth, margin stability, and continued innovation.
-
Strong Q3 results featured 21% revenue growth, expanding physician adoption, and robust gross margins. Product innovation and reimbursement tailwinds support continued growth, with new devices targeting large unmet needs and further market penetration expected.
-
Q3 2025 saw 21% revenue growth, positive adjusted EBITDA, and record physician additions. Guidance for 2025 was raised, with strong U.S. and international momentum, expanding product portfolio, and improving cash flow positioning the company for continued growth and profitability.
-
The business has evolved into a diversified, high-growth platform with strong innovation in sacropelvic solutions, robust financial performance, and expanding market penetration. Key growth drivers include new product launches, favorable reimbursement changes, and a stable, experienced leadership team.
-
Strong Q2 results and raised guidance reflect broad-based growth, margin expansion, and operational leverage. Favorable reimbursement, a robust product pipeline, and significant market opportunity position the business for sustained top-line growth and profitability into 2026.
-
Q2 2025 saw 22% revenue growth, record physician adoption, and positive adjusted EBITDA, with strong U.S. performance and early international momentum. Updated guidance reflects continued growth, margin expansion, and investments in innovation and capacity.
-
The company has expanded its product portfolio and market reach, driving record surgeon adoption and accelerating revenue growth. Strategic investments in R&D and sales force expansion support continued innovation and deeper market penetration, with strong financial performance and operating leverage.
-
Strong revenue and physician growth are driven by innovative, asset-light products addressing unmet needs in the sacral pelvic space. Industry-leading margins, expanding product portfolio, and robust physician education support sustainable profitability and long-term growth.
-
Strong Q1 results were driven by broad-based growth, new product adoption, and record physician engagement. Guidance remains prudent, with continued investment in innovation and commercial expansion. Interventional and core SI joint markets are key growth drivers, with new products set for 2026.
-
Q1 2025 saw 25% revenue growth, record physician engagement, and positive Adjusted EBITDA, driven by strong adoption of new products and expanding gross margins. Updated 2025 guidance projects 16–18% revenue growth and continued margin expansion.
Fiscal Year 2024
-
Record Q4 and full-year 2024 revenue growth was driven by strong product adoption, physician engagement, and new launches. Gross margin and profitability improved, with 2025 guidance projecting continued double-digit growth, margin expansion, and positive Adjusted EBITDA.
-
Strong growth continues with core SI joint fusion and new products Granite 9.5 and TNT expanding market reach. Despite a DOJ inquiry and hurricane-related headwinds, robust compliance, hybrid salesforce, and new reimbursement codes position the business for further margin expansion and growth in 2025.
-
Record Q3 revenue grew 19% year-over-year, with strong physician engagement and new product launches driving adoption. Profitability improved, and guidance was updated to reflect some case deferrals, but momentum remains strong with positive adjusted EBITDA expected in Q4.
-
The company is expanding its sacropelvic solutions platform with new products like Granite 9.5 and TNT, targeting a $3 billion TAM and focusing on increasing surgeon utilization and density. Revenue growth is guided at 19–20% for 2024, with profitability expected in 2025, supported by operating leverage and cost efficiencies.
-
Record Q2 revenue and physician growth were driven by strong product adoption and portfolio expansion. Adjusted EBITDA improved 43%, with breakeven expected in Q4 2024. New product launches and a hybrid sales model are fueling growth across core and emerging markets.
-
Q2 2024 saw record $40M revenue (up 20%), strong U.S. growth, and improved profitability. Guidance was raised for 2024, with accelerating growth and Adjusted EBITDA breakeven expected in Q4. New product launches, physician engagement, and robust liquidity support a positive outlook.
-
Targeting a $3B+ sacropelvic market, the company leads SI joint fusion with strong clinical data and new product launches like Granite 9.5 and Intra. With less than 10% market penetration, expanding physician engagement, and accelerating growth, profitability is expected soon.